Glaukos Corporation (GKOS) Stock Rating Reaffirmed by Stifel Nicolaus
Glaukos Corporation (NYSE:GKOS)‘s stock had its “buy” rating reiterated by equities researchers at Stifel Nicolaus in a research report issued on Thursday.
Several other equities analysts have also recently issued reports on GKOS. BidaskClub upgraded Glaukos Corporation from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Zacks Investment Research upgraded Glaukos Corporation from a “hold” rating to a “strong-buy” rating and set a $48.00 price target on the stock in a research report on Tuesday, July 4th. Roth Capital dropped their price target on Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating on the stock in a research report on Thursday, August 3rd. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $56.00 price target on shares of Glaukos Corporation in a research report on Thursday, August 3rd. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $53.33.
Shares of Glaukos Corporation (NYSE GKOS) traded down 18.12% during mid-day trading on Thursday, hitting $33.84. The stock had a trading volume of 6,153,027 shares. Glaukos Corporation has a 52-week low of $28.72 and a 52-week high of $52.49. The firm has a 50 day moving average price of $39.49 and a 200 day moving average price of $43.11. The firm’s market cap is $1.17 billion.
WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/09/14/glaukos-corporation-gkos-stock-rating-reaffirmed-by-stifel-nicolaus.html.
In other Glaukos Corporation news, Director Orbimed Advisors Llc sold 580,200 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $38.73, for a total transaction of $22,471,146.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Thomas William Burns sold 1,212 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $41.25, for a total value of $49,995.00. The disclosure for this sale can be found here. Insiders have sold a total of 980,200 shares of company stock worth $37,900,263 in the last three months. Corporate insiders own 16.40% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Engineers Gate Manager LP purchased a new position in shares of Glaukos Corporation during the 1st quarter worth $372,000. William Blair Investment Management LLC lifted its stake in shares of Glaukos Corporation by 5.3% during the 1st quarter. William Blair Investment Management LLC now owns 2,064,444 shares of the medical instruments supplier’s stock worth $105,906,000 after purchasing an additional 104,670 shares during the period. Teachers Advisors LLC lifted its stake in shares of Glaukos Corporation by 5.7% during the 4th quarter. Teachers Advisors LLC now owns 27,789 shares of the medical instruments supplier’s stock worth $953,000 after purchasing an additional 1,506 shares during the period. Parametric Portfolio Associates LLC lifted its stake in shares of Glaukos Corporation by 39.1% during the 1st quarter. Parametric Portfolio Associates LLC now owns 61,561 shares of the medical instruments supplier’s stock worth $3,158,000 after purchasing an additional 17,313 shares during the period. Finally, Alliancebernstein L.P. lifted its stake in shares of Glaukos Corporation by 43.6% during the 1st quarter. Alliancebernstein L.P. now owns 1,291,882 shares of the medical instruments supplier’s stock worth $66,274,000 after purchasing an additional 392,476 shares during the period.
About Glaukos Corporation
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.